TY - JOUR AU - Cobo, M.F.L.* AU - Pircher, C.* AU - Dietze, K.* AU - Kammertöns, T.* AU - Gary, R.* AU - Moosmann, A. AU - Mautner, J. AU - Dornmair, K.* AU - Takvorian, A.* AU - Bullinger, L.* AU - Blankenstein, T.* AU - Gerbitz, A.* AU - Hansmann, L.* C1 - 57088 C2 - 47478 CY - Macmillan Building, 4 Crinan St, London N1 9xw, England SP - 177-178 TI - Single cell identification of defined ebv epitope-specific TCR alpha beta pairs for adoptive T cell transfer against EBV infection and EBV-associated malignancies. JO - Bone Marrow Transplant. VL - 54 PB - Nature Publishing Group PY - 2019 SN - 0268-3369 ER - TY - JOUR AU - Freudenreich, M.* AU - Tischer, J.* AU - Kroell, T.* AU - Kremser, A.* AU - Dreyssig, J.* AU - Grabrucker, C.* AU - Liepert, A.* AU - Kolb, H.J.* AU - Schmid, C.* AU - Schmetzer, H. C1 - 57087 C2 - 47477 CY - Macmillan Building, 4 Crinan St, London N1 9xw, England SP - 145-145 TI - Clinical relevance of in vitro generation of dendritic cells of leukemic origin to predict response to immunotherapy in patients with AML and MDS. JO - Bone Marrow Transplant. VL - 54 PB - Nature Publishing Group PY - 2019 SN - 0268-3369 ER - TY - JOUR AU - Ritter, I.* AU - Gary, R.* AU - Seitz, V.* AU - Seegebarth, A.* AU - Wurdack, M.* AU - Moi, S.* AU - Mackensen, A.* AU - Aigner, M.* AU - Moosmann, A. AU - Henning, S.* AU - Hummel, M.* AU - Gerbitz, A.* C1 - 44465 C2 - 36965 CY - London SP - S400 TI - T-cell receptor deep sequencing analysis of EBV specific T cells before and after adoptive transfer in a patient after allogeneic stem cell transplantation. JO - Bone Marrow Transplant. VL - 50 PB - Nature Publishing Group PY - 2015 SN - 0268-3369 ER - TY - JOUR AU - Klar, R.* AU - Schober, S.* AU - Rami, M.* AU - Sarioglu, H. AU - Hauck, S.M. AU - Ueffing, M. AU - Admon, A.* AU - Barnea, E.* AU - Kremmer, E. AU - Oostendorp, R.* AU - Stevanovic, S.* AU - Busch, D.H.* AU - Peschel, C.* AU - Krackhardt, A.M.* C1 - 47028 C2 - 40485 SP - S74-S75 TI - Immunoproteomic identification of naturally presented epitopes presented on primary myeloid leukaemia cells and their potential as targets for T-cell receptor gene modified donor lymphocyte infusions. JO - Bone Marrow Transplant. VL - 48 PY - 2013 SN - 0268-3369 ER - TY - JOUR AB - We examined the role of total body magnetic resonance imaging (TB-MRI)-governed involved compartment irradiation (ICI) and high-dose chemotherapy (HDC), followed by stem cell rescue (SCR) in patients with high-risk Ewing tumors (ETs) with multiple primary bone metastases (high-risk ET-MBM). Eleven patients with high-risk ET-MBM receiving initial assessment of involved bones by TB-MRI were registered from 1995 to 2000 (group A). In all, 6 patients out of 11 had additional lung disease at initial diagnosis; all had multifocal bone disease with more than three bones involved. After systemic induction with etoposide, vincristine, adriamycin (doxorubicin), ifosfamide, and actinomycin D (EVAIA) or VAIA chemotherapy, ICI of all sites positive by TB-MRI was administered, followed by HDC and SCR. A second group matched for observation period and consisting of 26 patients with more than three involved bones at diagnosis was treated with the European Intergroup Cooperative Ewing Sarcoma Study-92 (EICESS-92) protocol (group B). These patients did not receive TB-MRI and consequently did not receive TB-MRI-governed ICI, or HDC and SCR. Survival in group A vs group B was 45 vs 8% at 5 years and 27 vs 8% at 10 years after diagnosis (log rank and Breslow: P AU - Burdach, S.* AU - Thiel, U.* AU - Schöniger, M.* AU - Haase, R.* AU - Wawer, A.* AU - Nathrath, M. AU - Kabisch, H.* AU - Urban, C.* AU - Laws, H.J.* AU - Dirksen, U. AU - Steinborn, M.* AU - Dunst, J.* AU - Jürgens, H.* C1 - 76 C2 - 26825 SP - 483-489 TI - Total body MRI-governed involved compartment irradiation combined with high-dose chemotherapy and stem cell rescue improves long-term survival in Ewing tumor patients with multiple primary bone metastases. JO - Bone Marrow Transplant. VL - 45 IS - 3 PY - 2010 SN - 0268-3369 ER - TY - JOUR AB - Donor lymphocyte infusions (DLIs) after allo-SCT displayed limited use in CLL and highly malignant non-Hodgkin's lymphoma (NHL). Here we studied whether Bi20 (FBTA05), a novel trifunctional bispecific antibody targeting CD20 on lymphoma cells and CD3 on T cells, could induce GVL responses in combination with DLI or mobilized PBSCT after allogeneic transplantation in these diseases. Six patients (three cases with p53-mutated CLL and three with high-grade NHL (HG-NHL)) refractory to standard therapy were treated with escalating doses of Bi20 (range 10-2000 mu g) followed by DLI or SCT. Thereby, all CLL patients showed a prompt but transient clinical and hematological response. In one patient with HG-NHL, we observed a halt in progression for almost 4 months. Side effects (fever, chills and bone pain) were tolerable and appeared at antibody dose levels between 40 and 200 mu g. The cytokine pro. le was characterized by transient increases of IL-6, IL-8 and IL-10. Neither human anti-mouse antibodies nor GVHD developed, allowing repeated treatment courses. In summary, the trifunctional antibody Bi20 induced prompt antitumor responses in extensively pretreated, p53-mutated alemtuzumab and rituximab refractory patients indicating its therapeutic potential. AU - Buhmann, R. AU - Simoes, B. AU - Stanglmaier, M.* AU - Yang, T. AU - Faltin, M.* AU - Bund, D. AU - Lindhofer, H.* AU - Kolb, H.-J. C1 - 153 C2 - 27061 SP - 383-397 TI - Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion. JO - Bone Marrow Transplant. VL - 43 IS - 5 PB - Nature Publ. Group PY - 2009 SN - 0268-3369 ER - TY - JOUR AU - Zorn, J. AU - Herber, M. AU - Schwamberger, S. AU - Adler, H. AU - Kolb, H.-. C1 - 47057 C2 - 40546 SP - S127-S128 TI - Tolerance in DLA-haploidentical canine littermates following CD6-depleted marrow transplantation and donor lymphocyte transfusion. JO - Bone Marrow Transplant. VL - 41 PY - 2008 SN - 0268-3369 ER - TY - JOUR AB - The Sixth International Symposium on Graft-versus-Host and Graft-versus Leukemia Reactions was held in Schloss Ellmau (near Garmisch-Partenkirchen, Germany) between January 21 and 24, 2004. A total of 110 invited participants (scientists and clinicians working in the area of allogeneic stem cell transplantation) discussed current topics. Major topics of the 2004 meeting were: clinical results of donor lymphocyte infusions, basic biology, immunogenetics, function and clinical relevance of natural killer cells, haplo-identical stem cell transplantation, immune monitoring and immune modulation. Further highlights were: adoptive immunotherapy, vaccination and antibody-mediated strategies. As can be seen in the summaries of the individual presentations, important advances have occurred in our understanding of GVH and GVL reactions. Each session was followed by an animated discussion, which resulted in new ideas, insights and projects both for basic research and clinical transplantation. This year's symposium ('From Marrow Transplantation to Cell Therapy') was jointly organized by the Ludwigs-Maximilians-University of Munich (Sonderforschungsbereich 455), GSF (National Research Center for Environment and Health) and the EBMT Immunobiology Working Party. The organizers and authors of the conference proceedings would like to extend their gratitude to all participants for sharing their ideas, slides and manuscripts and making this event possible. AU - Munker, R.* AU - Schmid, C.* AU - Madrigal, J.A.* AU - Kolb, H.-J. C1 - 1854 C2 - 22562 SP - 767-780 TI - An update on graft-versus-host and graft-versus-leukemia reactions: A summary of the sixth International Symposium held in Schloss Elmau. JO - Bone Marrow Transplant. VL - 34 IS - 9 PY - 2004 SN - 0268-3369 ER - TY - JOUR AB - The Fifth International Symposium on Graft-versus-Host and Graft-versus-Leukemia Reactions was held on 21 and 22 March 2002 in the University Hospital (Klinikum Grosshadern) of the University of Munich. As in previous years, it was dedicated to the encounter of scientists and clinicians involved in hematopoietic cell transplantation. This year's symposium focused on the characterization of stem cells potentially expanding the use of hematopoietic stem cells and on gene therapy. The immunology section dealt with mechanisms of tolerance, and the characterization of minor histocompatibility antigens presented by major histocompatibility molecules. Further important topics were cytokines and dendritic cells. In 1½ days of intense work, the invited speakers, chairmen, authors and an active audience experienced an exciting exchange of ideas and collaboration. Again, new impulses were given for basic research and clinical transplantation. The authors would like to express their deep appreciation and thanks to all participants of this symposium. AU - Munker, R.* AU - Günther, W. AU - Kolb, H.-J. C1 - 22314 C2 - 21131 SP - 549-556 TI - New concepts about graft-versus-host and graft-versus-leukaemia-reactions : a summary of the 5. International Symposium in Munich. JO - Bone Marrow Transplant. VL - 30 IS - 9 PY - 2002 SN - 0268-3369 ER - TY - JOUR AB - Antithymocyte globulin (ATG) is commonly used in allogeneic haematopoietic stem cell transplantation (HSCT). Little information is available, however, as to the optimal protocol for use and the side-effects occurring if ATG is administered in high daily doses (10-30 mg/kg). We report our experience with ATG Fresenius (ATG-F) in conditioning for allogeneic HSCT. During a period of 3 days, 47 patients received doses between 10 and 30 mg/kg either over 4 h preceded by 1-1.5 mg/kg prednisolone 30 min before the start of ATG-F (protocol A) or alternatively, over 12 h with 3-4 mg/kg prednisolone being administered before and 6 h after start of ATG (protocol B). During treatment with ATG-F, the side-effects observed included inflammation, disseminated intravascular coagulation, hyperdynamic circulation and renal dysfunction. Although these complications caused substantial morbidity, they were reversible within a few days. Side-effects were significantly more severe in patients treated according to protocol A than in those treated according to protocol B. As prolonged infusion of ATG-F does not reduce T cell clearance due to the long half-life of ATG-F, and since less cytokine release during conditioning might have beneficial long-term effects, we recommend administering ATG-F over 12 h preceded by high-dose steroid treatment. AU - Pihusch, R.* AU - Holler, E.* AU - Mühlbayer, D.* AU - Göhring, P.* AU - Stötzer, O.* AU - Hiller, E.* AU - Kolb, H.-J. C1 - 10325 C2 - 21074 SP - 347-354 TI - The impact of antithymocyte globulin on short-term toxicity after allogenic stem cell transplantation. JO - Bone Marrow Transplant. VL - 30 IS - 6 PY - 2002 SN - 0268-3369 ER - TY - JOUR AB - Following allogeneic hematopoietic stem cell transplantation (HSCT) patients may have an increased bleeding tendency in spite of a normal platelet count. Moreover, an association between chronic graft-versus-host disease (cGVHD) and a thrombophilic state has been observed. Platelet receptors and granules from 27 patients following HSCT (13 without cGVHD, 14 with cGVHD) were evaluated by flow cytometric analysis and compared to 62 healthy controls. Platelets from HSCT patients stained weakly with mepacrine indicating a reduced content of dense bodies, whereas no significant degranulation reaction of alpha granules and lysosomes was detectable. In addition, a lower surface expression of GP Ia/IIa was observed, indicating an acquired thrombocytopathy. The surface receptors are activated in HSCT patients, which could be seen by the lower surface expression of GP Ib internalized during the activation process and elevated levels of LIBS-1 and PAC-1 antibody binding. Patients with cGVHD had a seven-fold increased ratio of microparticles. This study demonstrates platelet receptor and granule defects in patients following HSCT. The key role of platelets in HSCT-associated hemostatic disorders is underscored by the high levels of circulating microparticles in cGvHD patients which might explain the thrombophilic state in these patients. AU - Pihusch, R.* AU - Wegner, H.* AU - Salat, C.* AU - Pihusch, M.* AU - Holler, E.* AU - Kolb, H.-J. AU - Hiller, E.* C1 - 10326 C2 - 21123 SP - 381-387 TI - Flow cytometric findings in platelets of patients following allogeneic hematopoietic stem cell transplantation. JO - Bone Marrow Transplant. VL - 30 IS - 6 PY - 2002 SN - 0268-3369 ER - TY - JOUR AB - IL-10 is a potent immunosuppressant which inhibits allo-antigen-specific T cell responses. In addition, IL-10 is a strong endogenous anti-inflammatory cytokine. To investigate the role of IL-10 in the induction of acute GVHD following allogeneic bone marrow transplantation (BMT) we performed a prospective study on spontaneous IL-10 production by peripheral blood mononuclear cells (PBMNC) in 84 patients admitted for allogeneic BMT. High spontaneous IL-10 production by PBMNC at the time of admission and prior to any preparative treatment correlated with a subsequent low incidence of GVHD and transplant-related mortality (8%), as compared to patients with low or intermediate IL-10 production (50%, P < 0.01). Our data demonstrate the prognostic significance of increased IL-10 production in BMT patients and suggest a major role of IL-10 in maintaining immunobalance in the setting of allogeneic BMT. AU - Holler, E. AU - Roncarolo, M.G.* AU - Hintermeier-Knabe, R.* AU - Eissner, G. AU - Ertl, B.* AU - Schulz, U.* AU - Knabe, H. AU - Kolb, H.-J. AU - Andreesen, R.* AU - Wilmanns, W.* C1 - 21551 C2 - 19675 SP - 237-241 TI - Prognostic significance of increased IL-10 production in patients prior to allogenic bone marrow transplantation. JO - Bone Marrow Transplant. VL - 25 IS - 3 PY - 2000 SN - 0268-3369 ER - TY - JOUR AB - An allogeneic tumor cell vaccine should display a natu- ral immunogenicity that allows the stimulation of tumor-reactive effector cells in patients. Furthermore, the vaccine should express antigens that are shared by many tumors to which patients are not tolerant. A var- iety of tumor peptides should be presented by different HLA-molecules due to limited MHC matching with recipients and last but not least, the vaccine should have a strong growth potential in vitro to allow adequate amounts of vaccine to be generated for long-term usage. In vitro and in situ studies with the renal cell carcinoma cell line RCC-26 demonstrate: (1) RCC-26 can induce complex allospecific responses through direct priming; (2) RCC-26 can not only reactivate cytotoxic T lympho- cytes (CTL) of a memory phenotype but they also can induce de novo tumor-antigen associated responses in normal donors; (3) these cells present epitopes restric- ted by several MHC molecules, allowing the vaccination of patients matched for different HLA alleles; and (4) they stimulate HLA-A*0201-restricted T cells bear- ing characteristic T cell receptors (TCR). Thus, in addition to using limiting dilution killer and ELISPOT assays, molecular tracking of a tumor-specific TCR can be used to judge the development of antitumor reac- tivity and vaccine efficiency. AU - Pohla, H.* AU - Frankenberger, B. AU - Stadlbauer, B.* AU - Oberneder, R.* AU - Hofstetter, A.* AU - Willimsky, G.* AU - Pezzutto, A.* AU - Dörken, B.* AU - Blankenstein, T.* AU - Schendel, D.J. C1 - 21354 C2 - 19470 SP - 83-87 TI - Allogeneic vaccianation for renal cell carcinoma: development and monitoring. JO - Bone Marrow Transplant. VL - 25 PY - 2000 SN - 0268-3369 ER - TY - JOUR AU - Bornkamm, G.W. AU - Jacobsen, N.R. C1 - 40392 C2 - 0 SP - S88-S89 TI - Viral infections and antiviral immunity. JO - Bone Marrow Transplant. VL - 12 IS - SUPPL. 4 PY - 1993 SN - 0268-3369 ER - TY - JOUR AU - Dörmer, P. AU - Gianni, A.M. C1 - 20610 C2 - 13821 SP - 120-122 TI - Stem cell physiology - role of CD34. JO - Bone Marrow Transplant. VL - 12 (Suppl.4) PY - 1993 SN - 0268-3369 ER - TY - JOUR AU - Dörmér, P.G. AU - Gianni, A.M. C1 - 40321 C2 - 0 SP - S120-S122 TI - Stem cell physiology - Role of CD34. JO - Bone Marrow Transplant. VL - 12 PY - 1993 SN - 0268-3369 ER - TY - JOUR AU - Holler., E. AU - Kolb, H.J. AU - Wilmanns, W. C1 - 33944 C2 - 35444 SP - S29-S31 TI - Treatment of GVHD-TNF-antibodies and related antagonists. JO - Bone Marrow Transplant. VL - 12 IS - SUPPL. 3 PY - 1993 SN - 0268-3369 ER - TY - JOUR AU - Thierfelder, S.S. C1 - 40393 C2 - 0 SP - S6-S8 TI - Antibody-induced suppression of graft versus host disease, animal models. JO - Bone Marrow Transplant. VL - 12 IS - SUPPL. 4 PY - 1993 SN - 0268-3369 ER - TY - JOUR AB - Cancer may be serious late effect of marrow transplantation. Radiation, chemotherapy, immunosuppression and the original disease for which transplantation was performed may predispose to the development of cancer. 116 of 9732 patients reported to the IBMTR (International Bone Marrow Transplant Registry) have developed a new malignancy. Late effects were evaluated by the EBMT-EULEP (European Bone Marrow Transplant - European Late Effect Project) Late Effect Study Group in 147 patients surviving 6 years and 79 patients surviving more than 10 years. New malignancies developed in 11 of these patients. Lymphomas and leukemia comprised 73 cases reported to the IBMTR and one case reported to the EBMT-EULEP study. Tumors of the skin, oropharynx, vulva vagina and cervix prevailed in 41 patients with solid tumors. The distribution of malignancies is similar to that observed in organ transplant patients not given radiation or chemotherapy and suggests immunosuppression as a major contributory factor. In dogs the incidence of malignancies was studied after either chemotherapy or total body radiation in various regimens and marrow transplantation. Both chemotherapy and radiation shortened tumorfree survival in comparison to untreated dogs. Higher doses, larger fractions and shorter treatment schedules enhanced earlier tumor development. Soft tissue sarcomas and thyroid carcinoma were most frequent in treated, mammary carcinoma in untreated dogs. In treated dogs deaths from cancer were observed starting at the age of 5 years as compared to untreated dogs at the age of 9 years. The data from animal experiments indicate that the incidence of solid tumors in marrow transplant patients may still rise in the coming decades. AU - Kolb, H.J. AU - Guenther, W. AU - Duell, T.H.G. AU - Soçié, G.J. AU - Schaeffer, E.H. AU - Holler., E. AU - Schumm, M.A. AU - Horowitz, M.M. AU - Gale, R.P. AU - Fliedner, T.M. C1 - 40493 C2 - 0 SP - 135-138 TI - Cancer after bone marrow transplantation. JO - Bone Marrow Transplant. VL - 10 IS - SUPPL. 1 PY - 1992 SN - 0268-3369 ER -